PE20000348A1 - PHARMACEUTICAL COMPOSITION INCLUDING A MATRIX METALOPROTEASE (MMP) INHIBITOR AND A STATIN - Google Patents
PHARMACEUTICAL COMPOSITION INCLUDING A MATRIX METALOPROTEASE (MMP) INHIBITOR AND A STATINInfo
- Publication number
- PE20000348A1 PE20000348A1 PE1999000217A PE00021799A PE20000348A1 PE 20000348 A1 PE20000348 A1 PE 20000348A1 PE 1999000217 A PE1999000217 A PE 1999000217A PE 00021799 A PE00021799 A PE 00021799A PE 20000348 A1 PE20000348 A1 PE 20000348A1
- Authority
- PE
- Peru
- Prior art keywords
- statin
- inhibitor
- pharmaceutical composition
- mmp
- alkyl
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 abstract 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 2
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 abstract 1
- -1 AMINO Chemical class 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 abstract 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 229960005110 cerivastatin Drugs 0.000 abstract 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004351 coronary vessel Anatomy 0.000 abstract 1
- 229950003040 dalvastatin Drugs 0.000 abstract 1
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 abstract 1
- 229960003765 fluvastatin Drugs 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 229950009116 mevastatin Drugs 0.000 abstract 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UN INHIBIDOR DE METALOPROTEASA DE MATRIZ DE FORMULA I, DONDE A ES FENILO, R1 ES ALQUILO, ARILO, HALOGENO, AMINO, ALCOXI; R2 ES CARBOXIALQUILCETONA, OXIMA, CARBOXIALQUILSULFONAMIDA COMO -SO2NHC(-R3)HCOOH; R3 ES ALQUILO C1-C10, ALCOXI C1-C10, SIENDO UN COMPUESTO PREFERIDO 2-(4`-BROMOBIFENIL-4-SULFONILAMINO)-3-METILBUTIRICO; b)UNA ESTATINA TAL COMO ATORVASTATINA, SIMVASTATINA, PRAVASTATINA, RIVASTATINA, MEVASTATINA, FLUINDOSTATINA, VELOSTATINA, FLUVASTATINA, DALVASTATINA, DIHIDROCOMPACTINA, COMPACTINA, CERIVASTATINA, LOVASTATINA; c)UN DILUYENTE. LA COMBINACION DE LOS COMPONENTES TIENEN UN EFECTO SINERGICO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE ANGINA DE PECHO, RIESGO CARDIACO, ATEROSCLEROSIS; RETARDANDO EL AVANCE DE LA PLACAS ATEROSCLEROTICAS EN LAS ARTERIAS CORONARIAS, CAROTIDAS, SISTEMA ARTERIAL PERIFERICOIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES a) A METALOPROTEASE INHIBITOR OF FORMULA I MATRIX, WHERE A IS PHENYL, R1 IS ALKYL, ARYL, HALOGEN, AMINO, ALCOXI; R2 IS CARBOXYALKYLKETONE, OXYME, CARBOXYALKYLSULFONAMIDE AS -SO2NHC (-R3) HCOOH; R3 IS C1-C10 ALKYL, C1-C10 ALCOXY, A PREFERRED COMPOUND BEING 2- (4`-BROMOBIPHENYL-4-SULFONYLAMINE) -3-METHYLBUTYRICO; b) A STATIN SUCH AS ATORVASTATIN, SIMVASTATIN, PRAVASTATIN, RIVASTATIN, MEVASTATIN, FLUINDOSTATIN, VELOSTATIN, FLUVASTATIN, DALVASTATIN, DIHYDROCOMPACTIN, COMPACTIN, CERIVASTATIN, LOVASTATIN; c) A THINNER. THE COMBINATION OF THE COMPONENTS HAVE A SYNERGIC EFFECT. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF ANGINA PECTORIS, CARDIAC RISK, ATHEROSCLEROSIS; DELAYING THE ADVANCE OF ATHEROSCLEROTIC PLATES IN CORONARY ARTERIES, CAROTIDED, PERIPHERAL ARTERIAL SYSTEM
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7826598P | 1998-03-17 | 1998-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000348A1 true PE20000348A1 (en) | 2000-05-22 |
Family
ID=22142950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000217A PE20000348A1 (en) | 1998-03-17 | 1999-03-16 | PHARMACEUTICAL COMPOSITION INCLUDING A MATRIX METALOPROTEASE (MMP) INHIBITOR AND A STATIN |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1063991A1 (en) |
| JP (1) | JP2002506818A (en) |
| KR (1) | KR20010041916A (en) |
| AR (1) | AR018113A1 (en) |
| AU (1) | AU1591699A (en) |
| BR (1) | BR9815745A (en) |
| CA (1) | CA2309588A1 (en) |
| CO (1) | CO5070670A1 (en) |
| GT (1) | GT199900039A (en) |
| HN (1) | HN1999000029A (en) |
| MY (1) | MY140504A (en) |
| NZ (1) | NZ505994A (en) |
| PA (1) | PA8469001A1 (en) |
| PE (1) | PE20000348A1 (en) |
| SV (1) | SV1999000026A (en) |
| UY (1) | UY25436A1 (en) |
| WO (1) | WO1999047138A1 (en) |
| ZA (1) | ZA992106B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
| GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
| AU2005315608B2 (en) | 2004-12-15 | 2011-03-31 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors |
| JP2009514851A (en) * | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | (3R, 5R) -7- [2- (4-Fluorophenyl) -5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino) carbonyl] -pyrrol-1-yl] -3,5 -Preparation of dihydroxy-heptanoic acid hemi-calcium salt |
| WO2010005389A1 (en) * | 2008-07-11 | 2010-01-14 | Forskarpatent I Syd Ab | Oxidized ldl specific antibody-fusion and conjugated proteins |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL123902A (en) * | 1995-11-02 | 2003-01-12 | Warner Lambert Co | PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR |
| ES2167733T3 (en) * | 1996-05-17 | 2002-05-16 | Warner Lambert Co | BIFENYLSULFONAMIDE MATRIX METALOPROTEINASE INHIBITORS. |
| CA2263886A1 (en) * | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| GT199800126A (en) * | 1997-08-29 | 2000-01-29 | COMBINATION THERAPY. |
-
1998
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/en not_active Ceased
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/en not_active Application Discontinuation
- 1998-11-20 EP EP98960279A patent/EP1063991A1/en not_active Withdrawn
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/en active Pending
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/en not_active Ceased
- 1998-11-20 NZ NZ505994A patent/NZ505994A/en unknown
- 1998-11-20 CA CA002309588A patent/CA2309588A1/en not_active Abandoned
-
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/en unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 CO CO99016109A patent/CO5070670A1/en unknown
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/en not_active Application Discontinuation
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/en unknown
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/en not_active Application Discontinuation
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/en unknown
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/en unknown
- 1999-03-16 GT GT199900039A patent/GT199900039A/en unknown
- 1999-03-16 UY UY25436A patent/UY25436A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999047138A1 (en) | 1999-09-23 |
| MY140504A (en) | 2009-12-31 |
| ZA992106B (en) | 1999-09-30 |
| UY25436A1 (en) | 2001-10-25 |
| CO5070670A1 (en) | 2001-08-28 |
| KR20010041916A (en) | 2001-05-25 |
| EP1063991A1 (en) | 2001-01-03 |
| GT199900039A (en) | 2000-09-06 |
| PA8469001A1 (en) | 2002-09-17 |
| AR018113A1 (en) | 2001-10-31 |
| NZ505994A (en) | 2003-10-31 |
| JP2002506818A (en) | 2002-03-05 |
| BR9815745A (en) | 2000-11-14 |
| HN1999000029A (en) | 1999-09-29 |
| SV1999000026A (en) | 2000-01-18 |
| AU1591699A (en) | 1999-10-11 |
| CA2309588A1 (en) | 1999-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241674T1 (en) | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS A PCSK9 INHIBITOR AND METHODS OF USE THEREOF | |
| JP2022116083A5 (en) | ||
| AR018777A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF A STATIN AND ASPIRINE AND METHOD. | |
| AR103624A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | |
| JP2002501887A5 (en) | Use of a plasma triglyceride level lowering agent for the manufacture of a medicament for the treatment of Alzheimer's disease | |
| RU2012116079A (en) | PHARMACEUTICAL COMPOSITION, INCLUDING OMEGA-3 FATTY ACID AND HYDROXY DERIVATED STATIN AND WAYS OF ITS APPLICATION | |
| BG105559A (en) | STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR | |
| DK0753298T3 (en) | Synergistic combination comprising an insulin sensitizing agent and an HMG-CoA reductase inhibitor for the treatment of arteriosclerosis | |
| MX2009003920A (en) | Statin and omega-3 fatty acids for reduction of apo-b levels. | |
| JP2018504438A5 (en) | ||
| TR200302281T2 (en) | Processes for preparing calcium salt forms of statins | |
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| PE20001047A1 (en) | METHOD TO TREAT ATHEROSCLEROSIS USING AN AP2 INHIBITOR AND COMBINATION | |
| PE20000017A1 (en) | STATINE-CARBOXIALKYL ETHER COMBINATIONS | |
| DK1626716T3 (en) | Nitric oxide derivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-lowering agents with enhanced anti-inflammatory, antithrombotic and anti-platelet activity | |
| AR081032A1 (en) | PHARMACEUTICAL FORMULATION IN THE FORM OF TWO-COATED TABLETS THAT INCLUDE INHIBITOR OF HMG-COA REDUCTASA AND IRBESARTAN | |
| PE20000348A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A MATRIX METALOPROTEASE (MMP) INHIBITOR AND A STATIN | |
| JP2007512347A5 (en) | ||
| JP2002508320A5 (en) | ||
| CY1105429T1 (en) | PHARMACEUTICAL COMPOSITION COMBINATING TENATOPRAZOLE AND AN ANTI-INFLAMMATORY | |
| BR0215602A (en) | boronate esters | |
| AR080023A1 (en) | FORMULATION OF COMPLEXES THAT INCLUDES ASPIRINE COVERED WITH A BARRIER CONTAINING HYDROPHOBE ADDITIVE AND INHIBITOR OF HMG-COA REDUCTASA | |
| JP2007530528A5 (en) | ||
| UY29979A1 (en) | SPIROCICLIC DERIVATIVES | |
| JP2002506818A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |